Dr Peter Meintjes commences as Pacific Edge Chief Executive
Company Announcement
19 January 2022
DR PETER MEINTJES COMMENCES AS PACIFIC EDGE CHIEF EXECUTIVE OFFICER
Cancer diagnostics company Pacific Edge (NZX: PEB, ASX: PEB) announces Dr Peter Meintjes commenced as Chief
Executive Officer of the company on 17 January.
As announced in October 2021, Dr Meintjes replaces Executive Director and Chief Executive David Darling, who
announced his retirement in April 2021.
Pacific Edge Chairman Chris Gallaher said: “We are delighted to welcome Peter to Pacific Edge. We are confident
his deep experience in molecular diagnostics, particularly in the US market, will be of tremendous value as the
company moves into its next phase of growth.”
Dr Meintjes, who has relocated from Boston to New Zealand with his family, will be based in the company’s Dunedin
Head Office.
Peter succeeds David Darling who has now stepped down as CEO and as a Director on the Pacific Edge Board. He
remains as a consultant to the company.
For more information contact: Dr Peter Meintjes, Pacific Edge. P: +64 22 0321 263 E: peter.meintjes@pelnz.com
For media assistance, please contact: Richard Inder, The Project. P: +64 21 645 643 E: richard@theproject.co.nz
OVERVIEW www.pacificedge.co.nz www.pacificedgedx.com
Pacific Edge Limited (NZX: PEB) is a New Zealand publicly listed, cancer diagnostic company specialising in the discovery and
commercialisation of diagnostic and prognostic tests for better detection and management of cancer. Its Cxbladder suite of
non-invasive, simple to use and accurate diagnostic tests provide actionable results, and better detection and management of
urothelial cancer. The company is developing and commercialising its range of Cxbladder bladder cancer tests globally through
its wholly owned central laboratories in New Zealand and the USA. The company’s products have been tested and validated in
international multi-centre clinical studies.
ABOUT Cxbladder Triage www.cxbladder.com
Cxbladder Triage combines the power of the genomic biomarkers with additional phenotypic and clinical risk factors to
accurately identify patients with haematuria who have a low probability of bladder cancer and may not require a more
extensive urological evaluation. Cxbladder Triage is a tool for use by clinicians and physicians in primary evaluation of patients
with haematuria and is intended to reduce the need for an expensive and invasive work-up in patients who have a low
probability of having urothelial carcinoma.
ABOUT Cxbladder Detect www.cxbladder.com
Cxbladder Detect enables the non-invasive detection of bladder and other urinary tract cancers from a small volume of a
patients’ urine. Cxbladder Detect provides clinicians with a quick, cost effective and accurate measure of the presence of the
cancer as an effective adjunct to cystoscopy.
ABOUT Cxbladder Monitor www.cxbladder.com
Cxbladder Monitor allows urologists to monitor bladder cancer patients for recurrence of the disease. Bladder cancer has a
recurrence rate of 50-80% and requires life-long surveillance. Cxbladder Monitor accurately identifies patients with a prior
history of urothelial cancer (UC) whose Cxbladder Monitor score shows that they have a low probability of recurrent urothelial
carcinoma. Cxbladder Monitor is designed to be used as the preferred adjunct test to cystoscopy in the management of patients
for ongoing evaluation of recurrent bladder cancer.
Company Announcement
19 January 2022
ABOUT Cxbladder Resolve www.cxbladder.com
Cxbladder Resolve identifies those patients who are likely to have aggressive or more advanced bladder cancer. Cxbladder
Resolve, when used as part of the primary evaluation of haematuria and/or in conjunction with other Cxbladder tests (Triage,
Detect), is designed to assist clinicians by accurately identifying patients with a high probability of having high grade or late-
stage bladder cancer, for whom alternative or expedited treatment options may be warranted, or who can be prioritised for
further investigation in high throughput settings.
Refer to www.cxbladder.com for more information.
Data sourced from publicly available filings. Our datasets may not be complete. Automated analysis can produce errors. If you believe any data on this page is incorrect, please contact us at hello@nzxplorer.co.nz. For informational purposes only. Not investment advice.
Other issuers discussed similar conditions around this time
Matched by meaning across NZX announcement text, not keywords — based on our semantic index of announcement bodies.
- MEL — Meridian Energy Limited: Meridian makes two appointments to Executive Team2022-03-30
“Release M e r i d i a n E n e r g y L i m i t e d ( A R B N 1 5 1 8 0 0 3 9 6 ) A c o m p a n y i n c o r p o r a t e d i n N e w Z e a l a n d L e v e l 2 , 5 5 L a d y E l i z a b e t h L a n e , P O B o x 1 0 8 4 0 , W e…”
- NZX — NZX Limited: NZX Board announces director change2021-11-23
“Mr Jessup’s appointment is effective 01 January 2022. Mr Jessup will join NZX’s Audit and Risk Committee and remain a member of the Technology Committee taking the role of Chair of that committee. As required by Listing Rule 2.6.2 the Board has determined that Peter is an inde…”
- WBC — Westpac Banking Corporation: Westpac 2021 Group Annual Report2021-10-31
“Group General Counsel & Enterprise Executive Rebecca is responsible for leading Westpac’s legal function globally, as well as leading the CEO’s office. Rebecca joined Westpac in 2002 and has held a variety of other senior leadership roles including General Manager, Human…”